Physician profile
Maria Collado
NPI 1073817383
$23,077.23
in general payments reported to CMS, 2019-2025
20 companies · $5,572 in 2025
The $5,572 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $1,226 · 2021: $1,153 · 2022: $8,919 · 2023: $1,903 · 2024: $3,380 · 2025: $5,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,520 · Food and Beverage: $5,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,520.00 |
| Food and Beverage | $5,334.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $8,826.70 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $6,088.77 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $1,704.57 | 2019-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $1,397.81 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Indivior INC. | $1,161.75 | 2019-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $949.35 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $667.32 | 2020-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $520.60 | 2019-2025 | Ingrezza |
| Abbvie INC. | $481.48 | 2021-2025 | Vraylar |
| Almatica Pharma LLC | $271.50 | 2021-2024 | Loreev Xr, Venlafaxine, Citalopram |
| Allergan, INC. | $243.70 | 2019-2020 | |
| Luye Pharma (USA) LTD. | $238.66 | 2025 | Erzofri Extended-Release |
| Lundbeck LLC | $158.57 | 2020-2025 | Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.46 | 2024 | |
| Vanda Pharmaceuticals INC. | $72.15 | 2022-2025 | Fanapt, Hetlioz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $62.88 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $52.61 | 2019 | |
| Procyrion, INC. | $25.77 | 2023 | Aortix System |
| Acadia Pharmaceuticals INC | $20.69 | 2024 | Nuplazid |
| Eisai INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Collado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.